electroCore 3Q 2026: Revenue $9.69M, Net loss $1.34M — 10-Q Summary

What happened

electroCore reported third-quarter 2026 revenue of $9.69 million, up 11.5% from a year earlier, and a net loss of $1.34 million, compared with $3.41 million. Quell Fibromyalgia and prescription gammaCore sales drove growth; an indemnification settlement gain also helped narrow the loss.

Confirmed

Global impact / market context

Higher sales and a smaller reported loss suggest improving business performance, but the settlement gain means the loss comparison was not driven solely by operations. Sales growth tied to specific products and government prescriptions makes continued demand and distribution execution important to future revenue.

Analyst inference

Nine-month sales rose 26% to $28.7 million, led by VA prescription sales, and management expects most 2026 revenue from VA prescription products. Since August, VA and Department of Defense prescription sales have moved to Lovell distribution, making that channel’s performance central to revenue continuity.

Confirmed

What to watch

1. Watch whether VA and Department of Defense sales through Lovell sustain prescription gammaCore revenue after the distribution transition that began in August 2026. Analyst inference
2. Track the FDA’s response to electroCore’s 510(k) application, which seeks clearance for Quell to treat chronic chemotherapy-induced peripheral neuropathy. Proposed
3. Watch whether planned sales, marketing, and research spending supports product demand and revenue without preventing further improvement in the company’s net loss. Analyst inference

Evidence

• Original source link unavailable